David Hecht

Summary

Affiliation: Loyola University Medical Center
Country: USA

Publications

  1. ncbi Characterization of BctA, a mating apparatus protein required for transfer of the Bacteroides fragilis conjugal element BTF-37
    David W Hecht
    Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA
    Res Microbiol 158:600-7. 2007
  2. ncbi Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing
    David W Hecht
    Hines VA Hospital, Loyola University Medical Center, 2160 S. First Avenue, Maywood, IL 60153, USA
    Anaerobe 12:115-21. 2006
  3. ncbi Evolution of anaerobe susceptibility testing in the United States
    David W Hecht
    Infectious Diseases Division, Loyola University Medical Center, and Hines VA Hospital, Maywood, IL, USA
    Clin Infect Dis 35:S28-35. 2002
  4. ncbi Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates
    David W Hecht
    Hines VA Hospital, Hines, Illinois, USA
    Antimicrob Agents Chemother 47:910-6. 2003
  5. ncbi Antibiotics and anaerobes of gut origin
    Gayatri Vedantam
    Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA
    Curr Opin Microbiol 6:457-61. 2003
  6. ncbi Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments
    David W Hecht
    Hines Veterans Affairs Hospital, Hines, USA
    Clin Infect Dis 39:92-7. 2004
  7. ncbi In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004
    David W Hecht
    Microbiology and Immunology, Loyola University Medical Center, Maywood, IL 60153, USA
    Antimicrob Agents Chemother 51:2716-9. 2007
  8. ncbi Implementing computerized provider order entry with an existing clinical information system
    William M Barron
    Loyola University Medical Center, Maywood, Illinois, USA
    Jt Comm J Qual Patient Saf 32:506-16. 2006
  9. ncbi Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile
    Jennifer R O'Connor
    Hines VA Hospital, 5000 South 5th Ave, Hines, IL 60141 3030, USA
    Antimicrob Agents Chemother 52:2813-7. 2008
  10. ncbi Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment
    Stuart Johnson
    Research Service, Hines VA Hospital, Hines, IL 60141 3030, USA
    Anaerobe 15:290-1. 2009

Research Grants

  1. Efficient Mechanism of Gene Transfer in B. fragilis
    David Hecht; Fiscal Year: 2006

Collaborators

Detail Information

Publications18

  1. ncbi Characterization of BctA, a mating apparatus protein required for transfer of the Bacteroides fragilis conjugal element BTF-37
    David W Hecht
    Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA
    Res Microbiol 158:600-7. 2007
    ....
  2. ncbi Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing
    David W Hecht
    Hines VA Hospital, Loyola University Medical Center, 2160 S. First Avenue, Maywood, IL 60153, USA
    Anaerobe 12:115-21. 2006
  3. ncbi Evolution of anaerobe susceptibility testing in the United States
    David W Hecht
    Infectious Diseases Division, Loyola University Medical Center, and Hines VA Hospital, Maywood, IL, USA
    Clin Infect Dis 35:S28-35. 2002
    ....
  4. ncbi Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates
    David W Hecht
    Hines VA Hospital, Hines, Illinois, USA
    Antimicrob Agents Chemother 47:910-6. 2003
    ..Among the fluoroquinolones, garenoxacin and trovafloxacin had an MIC at which 90% of the isolates tested were inhibited of <4 micro g/ml for all but two species (Fusobacterium mortiferum/varium and Peptostreptococcus anaerobius)...
  5. ncbi Antibiotics and anaerobes of gut origin
    Gayatri Vedantam
    Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA
    Curr Opin Microbiol 6:457-61. 2003
    ....
  6. ncbi Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments
    David W Hecht
    Hines Veterans Affairs Hospital, Hines, USA
    Clin Infect Dis 39:92-7. 2004
    ..The use of standardized testing methods that recognize resistance and an understanding of resistance mechanisms have become essential for the treatment of patients and the development of new agents...
  7. ncbi In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004
    David W Hecht
    Microbiology and Immunology, Loyola University Medical Center, Maywood, IL 60153, USA
    Antimicrob Agents Chemother 51:2716-9. 2007
    ..These in vitro susceptibility results are encouraging and support continued evaluation of selected antimicrobials in clinical trials of treatment for CDAD...
  8. ncbi Implementing computerized provider order entry with an existing clinical information system
    William M Barron
    Loyola University Medical Center, Maywood, Illinois, USA
    Jt Comm J Qual Patient Saf 32:506-16. 2006
    ..There are numerous barriers to successfully implementing computerized provider order entry (CPOE), and it is not entirely clear to what degree the proposed benefits extend to older, commercially available systems in place at most hospitals...
  9. ncbi Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile
    Jennifer R O'Connor
    Hines VA Hospital, 5000 South 5th Ave, Hines, IL 60141 3030, USA
    Antimicrob Agents Chemother 52:2813-7. 2008
    ..We propose that rifaximin resistance in C. difficile results from mutations in RpoB and that rifampin resistance predicts rifaximin resistance for this organism...
  10. ncbi Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment
    Stuart Johnson
    Research Service, Hines VA Hospital, Hines, IL 60141 3030, USA
    Anaerobe 15:290-1. 2009
    ..C. difficile isolates from one of the two patients who failed treatment had an MIC of >256 microg/ml to rifampin. Serial therapy with vancomycin, followed by rifaximin remains an option for some patients with multiple CDI recurrences...
  11. ncbi Bacteroides fragilis mobilizable transposon Tn5520 requires a 71 base pair origin of transfer sequence and a single mobilization protein for relaxosome formation during conjugation
    Gayatri Vedantam
    Department of Medicine, Loyola University Medical Center, Maywood, IL, USA
    Mol Microbiol 59:288-300. 2006
    ..We hypothesize that transposon-based single Mob protein systems may contribute to efficient gene dissemination from Bacteroides spp., because fewer DNA processing proteins are required for relaxosome formation...
  12. ncbi Interaction of Bacteroides fragilis pLV22a relaxase and transfer DNA with Escherichia coli RP4-TraG coupling protein
    Johnson Thomas
    Program in Molecular Biology, Loyola University Medical Center, Maywood, IL, USA
    Mol Microbiol 66:948-60. 2007
    ..Thus, mobilization of the Bacteroides pLV22a in E. coli utilizes both RP4 Mpf and CP functions including an interaction between the relaxosome and the RP4 CP similar to that of cognate RP4 plasmid...
  13. ncbi Isolation and characterization of cLV25, a Bacteroides fragilis chromosomal transfer factor resembling multiple Bacteroides sp. mobilizable transposons
    Kathleen A Bass
    Department of Medicine, Hines VA Hospital, Hines, Illinois 60141, USA
    J Bacteriol 184:1895-904. 2002
    ..transfer factors, including NBU1, NBU2, CTnDOT, Tn4555, and Tn5520...
  14. ncbi Isolation and characterization of BTF-37: chromosomal DNA captured from Bacteroides fragilis that confers self-transferability and expresses a pilus-like structure in Bacteroides spp. and Escherichia coli
    Gayatri Vedantam
    Departments of Medicine and Microbiology/Immunology and Program in Molecular Biology, Loyola University Medical Center, 2160 S. First Ave, Maywood, IL 60153, USA
    J Bacteriol 184:728-38. 2002
    ..coli broad-host-range plasmids. We conclude that we have captured a new, self-transferable transfer factor from B. fragilis LV23 and that this new factor encodes a tetracycline-inducible Bacteroides sp. conjugation apparatus...
  15. ncbi Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole
    Kelly A Sprandel
    College of Pharmacy, University of Illinois, Chicago, IL 60612, USA
    Diagn Microbiol Infect Dis 55:303-9. 2006
    ..Based on this model, attainment of the target pharmacodynamic parameter (AUC/MIC ratio >or=70) against B. fragilis isolates is >99% when MICs are <2 mg L(-1), irrespective of the dosing interval of 24 h...
  16. ncbi Molecular characterization of imipenem-resistant, cfiA-positive Bacteroides fragilis isolates from the USA, Hungary and Kuwait
    József Sóki
    Institute of Clinical Microbiology, University of Szeged, Szeged, Hungary
    J Med Microbiol 53:413-9. 2004
    ..On the basis of the available phenotypic and genotypic evidence, the present data suggest that there are at least two cfiA activation mechanisms among B. fragilis isolates...
  17. ncbi Routine anaerobic blood cultures: back where we started?
    David W Hecht
    Clin Infect Dis 44:901-3. 2007
  18. ncbi Emergence of fluoroquinolone resistance among Bacteroides species
    Yoav Golan
    Geographic Medicine and Infectious Diseases, Tufts New England Medical Center, Boston, MA, USA
    J Antimicrob Chemother 52:208-13. 2003
    ..Several newer generation fluoroquinolones have demonstrated good in vitro activity against Bacteroides species; particularly when first introduced. However, resistance of Bacteroides to quinolones appears to be increasing...

Research Grants5

  1. Efficient Mechanism of Gene Transfer in B. fragilis
    David Hecht; Fiscal Year: 2006
    ..abstract_text> ..